A.   Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

B.   Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

C.   Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events

D.   Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer

A.   Compliance with the fertility drugs

B.   Presence of abnormal uterine bleeding

C.   Current smoking status

D.   Current use of medications for depression

A.   The patient is ready for delivery.

B.   The contractions can be fatal to the patient.

C.   The fetal heart rate is stable.

D.   The patient’s blood pressure is stable.

A.   Luteinizing hormone (LH)

B.   Adrenocorticotropic hormone

C.   Follicle-stimulating hormone (FSH)

D.   Antidiuretic hormone

A.   Day 21

B.   Day 3

C.   Day 14

D.   Day 7

A.   Clomiphene

B.   Raloxifene

C.   Methylergonovine

D.   Megestrol

A.   Oxytocin

B.   Terbutaline

C.   Magnesium sulfate

D.   Methylergonovine

A.   Methylergonovine

B.   Indomethacin

C.   Medroxyprogesterone acetate

D.   Megestrol

A.   Luteinizing hormone (LH)

B.   Luteotropic hormone

C.   Follicle-stimulating hormone (FSH)

D.   Interstitial cell-stimulating hormone

A.   Biphasic

B.   Triphasic

C.   Extended-cycle

D.   Monophasic

A.   Phase 2

B.   Phase 3

C.   Phase 4

D.   Phase 1

A.   Alendronate

B.   Megestrol

C.   Medroxyprogesterone

D.   Esterified estrogens

A.   Termination of pregnancy

B.   Premature labor

C.   Postpartum hemorrhage

D.   Accelerated labor

A.   Dry skin

B.   Nausea

C.   Higher-pitched voice

D.   Weight loss

A.   Weight gain

B.   Thrombophlebitis

C.   Dysmenorrhea

D.   Hypertension

A.   Luteinizing hormone

B.   Adrenocorticotropic hormone

C.   Follicle-stimulating hormone

D.   Antidiuretic hormone

A.   Interference with the proliferation of the fertilized ovum

B.   Elevated progesterone levels inhibiting the release of the luteinizing hormone

C.   Diminished endometrial tissue proliferation

D.   Inhibition of the release of gonadotropins

A.   "The progestin in the regimen will help prevent breast cancer."

B.   "Endometrial cancer risk can be reduced by adding progestin."

C.   "The progestin in the regimen will help prevent ovarian cancer."

D.   "Vaginal cancer is prevented by adding progestin to the regimen."

A.   Dysmenorrhea

B.   Deep vein thrombosis

C.   Uterine bleeding

D.   Weight loss

A.   Ethinyl estradiol

B.   Clomiphene

C.   Progesterone

D.   Choriogonadotropin alfa

A.   Clomiphene

B.   Dinoprostone

C.   Oxytocin

D.   Indomethacin

A.   Administer acetaminophen as needed.

B.   Suggest the patient take aluminum hydroxide with the medication.

C.   Assess pulse oximetry continuously.

D.   Monitor the patient’s blood pressure frequently.

A.   Brown discoloration of face

B.   Hot flashes

C.   Loss of hair

D.   Yellow undertone to the skin

A.   Megestrol

B.   Estrone

C.   Estropipate

D.   Medroxyprogesterone

A.   Oxytocin

B.   Terbutaline

C.   Prostaglandin E

D.   Clomiphene

A.   Monotherapy with a progestin increases breast cancer risk.

B.   Estradiol with progestin increases the risk of endometrial cancer.

C.   Estrogen monotherapy increases the risk of breast cancer.

D.   Unopposed estrogen increases the risk of endometrial cancer.

A.   Sedentary lifestyle

B.   Smoking heavily every day

C.   Increased body mass index (BMI)

D.   Consumption of saturated fats

A.   To terminate pregnancy

B.   To treat gestational hypertension

C.   To induce cervical ripening

D.   To treat pelvic inflammatory disease

A.   Vertigo, Joint pain, Chest pain

B.   Chest pain, Hot flashes, Loss of appetite

C.   Hot flashes, Loss of appetite, Joint pain

D.   Hot flashes, Vertigo, Loss of appetite

A.   "I need to take this medication with food to prevent damage to my esophagus."

B.   "I need to decrease my intake of dairy products to prevent hypercalcemia."

C.   "This medication will help relieve the bone pain I have from my osteoporosis."

D.   "I will take the medication on an empty stomach and not lie down for 30 minutes."

A.   Multivitamin, Atenolol

B.   Warfarin, Cholestyramine

C.   Levothyroxine, Multivitamin

D.   Atenolol, Levothyroxine

A.   Promotes bone absorption of calcium

B.   Contains estrogen, which stimulates bone reabsorption

C.   Stimulates estrogen receptors on the bone to increase bone density

D.   Inhibits osteoclast-mediated bone reabsorption

A.   Metformin

B.   Levothyroxine

C.   Amoxicillin

D.   Ferritin

A.   "I am no longer experiencing painful intercourse."

B.   "I no longer experience hot flashes."

C.   "I have not experienced any uterine bleeding."

D.   "I have seen a great improvement in my sexual desire."

A.   "Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation."

B.   "High progesterone levels inhibit the release of luteinizing hormone."

C.   "Decreased Gn-RH suppresses the release of follicle-stimulating hormone."

D.   "Estrogen levels inhibit the release of follicle-stimulating hormone."

A.   "Report missed menstrual periods."

B.   "Have tests for serum cholesterol."

C.   "Have a yearly mammogram."

D.   "Perform weight-bearing exercise."

A.   "Space the medications 1 to 2 hours apart."

B.   "Obtain a prescription for increasing the bisphosphonate dose."

C.   "Replace the bisphosphonate with calcitonin."

D.   "Discontinue the calcium supplement."

A.   Breast cancer

B.   Joint pain

C.   Current smoker

D.   Allergy to salmon

A.   Norethindrone and ethinyl estradiol

B.   Male condom with spermicidal jelly

C.   Medroxyprogesterone

D.   Cervical cap with spermicidal jelly

A.   Antibiotic therapy

B.   Hypertension

C.   Anticonvulsant therapy

D.   Diabetes

A.   Bed rest and hydration

B.   Terbutaline

C.   Magnesium sulfate

D.   Ritodrine

A.   "The therapy may cause thromboembolic events."

B.   "The treatment should be started as soon as possible."

C.   "You may need to stop smoking during the therapy."

D.   "The treatment is likely to cause endometrial cancer."

A.   Persuade the patient to start the therapy.

B.   Ask the patient to include soy in her diet.

C.   Advise the patient to engage in quiet activities.

D.   Inform the patient about the benefits and risks of the therapy.

A.   Denosumab

B.   Calcitonin

C.   Tamoxifen

D.   Ibandronate

A.   The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

B.   Uterine hyperactivity, Fetal heart rate, Complete blood cell count

C.   Fetal movement, Uterine hyperactivity, Complete blood cell count

D.   Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

A.   Cigarette use

B.   Use of herbal supplements

C.   Low fluid intake

D.   Current tricyclic antidepressant use

A.   Absence of cervical ripening at 42 weeks’ gestation

B.   Ineffective contractions in a full-term pregnancy

C.   Radiographic confirmation of cephalopelvic disproportion

D.   Vaginal bleeding at 38 weeks’ gestation

A.   Blood glucose

B.   Blood pressure

C.   Temperature

D.   Uterine contractions

A.   Uterine atony

B.   Nausea and vomiting

C.   Hypertension

D.   Pelvic inflammatory disease

A.   Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B.   Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

C.   Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

D.   Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

A.   Immediately discontinue intravenous (IV) fluids.

B.   Instruct the patient to bear down and push.

C.   Administer phentolamine mesylate.

D.   Place the patient on her left side.

A.   Decrease the drug dose immediately.

B.   Request a prescription to give calcium gluconate.

C.   Obtain a prescription for terbutaline.

D.   Obtain a prescription for indomethacin.

A.   Atropine

B.   Calcium gluconate

C.   Epinephrine

D.   Protamine sulfate

A.   Methylergonovine

B.   Estradiol

C.   Alendronate

D.   Megestrol

A.   During the entire period the patient is taking the antibiotic

B.   For at least 6 weeks, starting at the end of the antibiotic regimen

C.   Until three throat cultures have been negative for the pathogen

D.   For at least 1 month after starting the antibiotic

A.   Hirsutism, Dizziness,, Increased diuresis

B.   Hirsutism, Bradycardia, Increased diuresis

C.   Blurred vision, Bradycardia, Increased diuresis

D.   Anxiety, Dizziness, Blurred vision

A.   Pulmonary embolism

B.   Ovarian failure

C.   Abnormal vaginal bleeding

D.   Renal failure

A.   Softened cervix

B.   Midline fundus

C.   Strong contractions

D.   Decreased pain